Categories Earnings, Other Industries

Allstate stock drops as Q3 profit misses estimates

The Allstate Corp. (ALL) reported a 31% jump in earnings for the third quarter helped by higher premiums earned, lower catastrophe losses and lower effective tax rate. However, the bottom line missed analysts expectations. Following this, the stock fell over 3% in the after-market session.

Net income applicable to common shareholders climbed 31% to $833 million and earnings soared 36% to $2.37 per share. Adjusted EPS increased 20.6% to $1.93.

The results were benefited by lower catastrophe losses and lower effective tax rate. This was partially offset by higher property and casualty insurance non-catastrophe claims losses, higher amortization of DAC for property and casualty businesses and Allstate Life.

An increase in insurance premiums drove total revenues higher by 5.8% to $10.47 billion. Insurance premiums increased in the following segments: Allstate Protection (Allstate brand and Esurance), Service Businesses, Allstate Benefits, and Allstate Life.

Hurricane Florence might not dent insurance industry as expected

The Property-Liability combined ratio increased to 94.3 from 93.9 in the previous year quarter. Net investment income was flat in the third quarter of 2018, compared to last year.

On October 31, 2018, the Board authorized a new $3 billion common share repurchase program that is expected to be completed by April 2020.

As of September 30, 2018, shareholders’ equity was $23.63 billion, including $3.38 billion in deployable assets at the parent holding company level comprising cash and investments that are generally saleable within one quarter.

Shares of Allstate ended Wednesday’s regular session up 0.24% at $95.72 on the NYSE. The stock has fallen over 8% in the year so far while it has risen over 1% in the past year.

 

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top